Jun Bao
Chief Executive Officer at IMPACT Therapeutics, Inc.
Net worth: 6 943 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Wei Chen | F | 57 | 1 years | |
| Xu Tian | F | 64 |
Beijing Shenogen Pharma Group Ltd.
 Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Wei Wang | F | 41 | 2 years | |
| Xiao Lu Weng | M | 47 | 3 years | |
| Kumar Srinivasan | M | 59 | 2 years | |
| Zhi Hua Zhang | M | 43 | 3 years | |
| Jia Song Tang | M | 50 | 3 years | |
| Shu Xue Wang | M | 48 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 9 years |
| Lei Zhu | F | 44 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 10 years |
| Jian Xun Liu | M | 69 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Ye Yan | F | 66 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Yong Peng | M | 62 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 6 years |
| Bao Ping Wang | M | 63 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 6 years |
| Yan Min Tang | F | 51 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Jun Fei Feng | M | 41 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Jun Xie | M | 55 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Bing Wu | M | 50 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Xiang Wu Ye | M | 72 |
BiTech Pharma, Inc.
 BiTech Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services BiTech Pharma, Inc. develops medicines. The private company is based in Emeryville, CA. Xiang Wu Ye has been the CEO of the company since 2008. | 16 years |
| San Guo Zhu | M | 74 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 8 years |
| Ye Edward Tian | M | - |
IMPACT Therapeutics, Inc.
 IMPACT Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology IMPACT Therapeutics, Inc. manufactures pharmaceutical products. The firm develops discovery and commercialization of novel therapeutics to treat cancer and other life-threatening diseases. The company was founded in 2009 and is headquartered in Nanjing, China. | - |
| Sheng Yu Feng | M | 66 |
Shandong University
| 40 years |
| Jun Feng Wang | M | 50 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Xiang Yi Xu | M | 68 |
Shandong University
| 42 years |
| Caroline Germa | M | 52 | 2 years | |
| Robert W. Lee | M | - |
University of Kansas
| 32 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Durk I. Jager | M | 81 | 30 years | |
| Da Zhu | M | 43 | - | |
| Robert Stockton | M | - |
The University of Chicago
| 4 years |
| Stephen T. Sigler | M | 54 |
University of Kansas
| 8 years |
| Michael Fonstein | M | 64 |
The University of Chicago
| 4 years |
| Samarth Chandra | M | - |
The University of Chicago
| 4 years |
| Sara Peng | F | - |
University of Kansas
| 4 years |
| Edwin Rigaud | M | 80 | 36 years | |
| Jason L. Wyman | M | - |
The University of Chicago
| 8 years |
| Jeremy D. Tasset | M | - |
University of Kansas
| 4 years |
| Meridith Alin | F | - |
The University of Chicago
| 4 years |
| Jasvindarjit Singh | M | - |
University of Kansas
| 12 years |
| Michael Maddox | M | 54 |
University of Kansas
| 7 years |
| Luis Garicano Gabilondo | M | - |
The University of Chicago
| 4 years |
| Li Ming Fan | F | 66 |
Shandong University
| 7 years |
| Sonia Marciano | M | 61 |
The University of Chicago
| 2 years |
| Lubin Wang | M | 68 |
Shandong University
| 6 years |
| Peter Kagan | M | 73 |
The University of Chicago
| 3 years |
| Scott Cook | M | 72 | 20 years | |
| Vartan Gregorian | M | 90 | 13 years | |
| Scott Stromatt | M | 66 | 5 years | |
| Ryan M. Sprott | M | 51 |
University of Kansas
| 5 years |
| Ernesto Zedillo Ponce de León | M | 71 | 18 years | |
| Johnathan A. Rodgers | M | 78 | 12 years | |
| S. Mathew | F | 68 | 18 years | |
| Richard E. Leigh | M | 64 | 1 years | |
| David Cheng | M | - |
The University of Chicago
| 4 years |
| Reagan Ammann | M | - |
The University of Chicago
| 2 years |
| Ben Garber | M | - |
The University of Chicago
| 4 years |
| Bryan T. Clark | M | - |
The University of Chicago
| 3 years |
| Tom Seftenberg | M | - |
The University of Chicago
| 2 years |
| Audra Lynn Lalley | F | - |
The University of Chicago
| 2 years |
| Dan J. Greifenkamp | M | - |
The University of Chicago
| 3 years |
| Christopher Joseph Clower | M | 59 |
The University of Chicago
| 2 years |
| Julio Pellegrini Vial | M | 50 |
The University of Chicago
| 3 years |
| M. Jay Cox | M | - |
The University of Chicago
| 2 years |
| Randall Posejpal | M | - |
The University of Chicago
| 2 years |
| Neil M. Bouhan | M | - |
The University of Chicago
| 4 years |
| Dan Trencher | M | - |
The University of Chicago
| 2 years |
| Joon Jeon | M | - |
The University of Chicago
| 4 years |
| James A. White | M | - |
The University of Chicago
| 2 years |
| Angela Pillar Maramag | F | 53 |
The University of Chicago
| 3 years |
| Yung-Shin Alexander Kung | M | - |
The University of Chicago
| 4 years |
| David Ansani | M | 59 |
The University of Chicago
| 2 years |
| Rizal Rickman bin Ramli | M | 47 |
The University of Chicago
| 4 years |
| Gauhar Turmuhambetova | M | - |
The University of Chicago
| 7 years |
| Rolf Johnsen | M | - |
The University of Chicago
| 2 years |
| Brian N. Wanek | M | - |
The University of Chicago
| 3 years |
| Christopher J. O'Malley | M | - |
The University of Chicago
| 2 years |
| Chip Miller | M | - |
The University of Chicago
| 2 years |
| Matthew Rothschild | M | - |
The University of Chicago
| 2 years |
| Patrick G. Boyce | M | - |
The University of Chicago
| 2 years |
| Sameer Kumar Sabharwal | M | - |
The University of Chicago
| 4 years |
| Matt Friedman | M | - |
The University of Chicago
| 2 years |
| Brian Newman | M | - |
The University of Chicago
| 3 years |
| Susie Hultquist | F | 56 |
The University of Chicago
| 2 years |
| Terry Kontos | M | - |
The University of Chicago
| 4 years |
| Matt Schechter | M | - |
The University of Chicago
| 4 years |
| Yuujiro Goto | M | - |
The University of Chicago
| 12 years |
| Jeff Mihalek | M | - |
The University of Chicago
| 4 years |
| Steven S. Fu | M | - |
The University of Chicago
| 3 years |
| Denis Labij | M | - |
The University of Chicago
| 2 years |
| Rob Rueckert | M | - |
The University of Chicago
| 2 years |
| Mark C. Abrahamsen | M | - |
The University of Chicago
| 2 years |
| Grégoire Dallemagne | M | 51 |
The University of Chicago
| 2 years |
| David Toussaint | M | - |
The University of Chicago
| 2 years |
| Carmen A. Heredia-Lopez | F | - |
The University of Chicago
| 2 years |
| Masahide Komatsu | M | - |
The University of Chicago
| 2 years |
| Woo Yong Cha | M | - |
The University of Chicago
| 3 years |
| David McMillan | M | - |
The University of Chicago
| 1 years |
| Andrew Strommen | M | - |
The University of Chicago
| 4 years |
| Mark Hanson | M | - |
The University of Chicago
| 4 years |
| Dan Kozlowski | M | 53 |
The University of Chicago
| 2 years |
| Cindy Galiano | F | 49 |
The University of Chicago
| 4 years |
| Henry Park | M | - |
The University of Chicago
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 74 | 74.00% |
| China | 26 | 26.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jun Bao
- Personal Network
